RSLS Stock Overview
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ReShape Lifesciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.17 |
| 52 Week High | US$2.80 |
| 52 Week Low | US$0.14 |
| Beta | 1.3 |
| 1 Month Change | 3.45% |
| 3 Month Change | -12.91% |
| 1 Year Change | -92.92% |
| 3 Year Change | -99.93% |
| 5 Year Change | -99.97% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)
Apr 18
ReShape wins FDA clearance for device used in weight loss surgery
Aug 10Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results
Mar 31Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?
Dec 09Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?
Aug 24Shareholder Returns
| RSLS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.9% | -0.5% | 1.6% |
| 1Y | -92.9% | -1.0% | 25.1% |
Return vs Industry: RSLS underperformed the US Medical Equipment industry which returned -1% over the past year.
Return vs Market: RSLS underperformed the US Market which returned 25.1% over the past year.
Price Volatility
| RSLS volatility | |
|---|---|
| RSLS Average Weekly Movement | 9.6% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RSLS has not had significant price volatility in the past 3 months.
Volatility Over Time: RSLS's weekly volatility has decreased from 15% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 29 | Paul Hickey | www.reshapelifesciences.com |
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual’s comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus.
ReShape Lifesciences Inc. Fundamentals Summary
| RSLS fundamental statistics | |
|---|---|
| Market cap | US$4.08m |
| Earnings (TTM) | -US$11.39m |
| Revenue (TTM) | US$8.68m |
0.5x
P/S Ratio-0.4x
P/E RatioIs RSLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RSLS income statement (TTM) | |
|---|---|
| Revenue | US$8.68m |
| Cost of Revenue | US$3.13m |
| Gross Profit | US$5.55m |
| Other Expenses | US$16.94m |
| Earnings | -US$11.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 63.93% |
| Net Profit Margin | -131.22% |
| Debt/Equity Ratio | 0% |
How did RSLS perform over the long term?
See historical performance and comparison